READNOUR ROBIN SHANE sold 5.3% of their position (35.40K shares) of AN2 THERAPEUTICS, INC. on the open market
Open‑market sale worth $212.7K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 8/19/2026ACC: 0001193125-26-357225
Director
Since Mar 2022
-35.40K
Net shares
Net seller
$212.7K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
35.40K disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
−16.70K
Price / share
$6.01
Trade value
$100.31K
% of position
2.9%
8/17/2026
582.29K→565.59K
Common Stock
Indirect
Shares
−18.71K
Price / share
$6.01
Trade value
$112.39K
% of position
2.9%
8/17/2026
652.57K→633.87K
Total
Net shares
−35.40K
Net value
-$212.70K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 8/17/2026 | S · Sale | −16.70K | $6.01 | $100.31K | 2.9% | 582.29K | 565.59K |
| Common Stock Indirect | 8/17/2026 | S · Sale | −18.71K | $6.01 | $112.39K | 2.9% | 652.57K | 633.87K |
| Total | −35.40K | -$212.70K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
DirectShares owned9.08K
Total
9.08K direct9.08K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 9.08K | Direct |
| Total | 9.08K | 9.08K direct |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported